Boston Scientific's Watchman

Thank you for taking our Predictive Intelligence survey where we, as a group, can better anticipate and plan for major market events. See below for how you can get the results of this survey once completing it.

Today's question pertains to the outcome of Boston Scientific's upcoming FDA’s Circulatory System Devices advisory panel on December 11, 2013 for the company's anti-stroke Watchman heart implant. The Watchman implant, already available in 30 countries, is introduced via catheter and threaded into the heart to close off the left atrial appendage and capture any blood clots that may form there.

Note: for the purpose of this survey, a 9-0 decision with one abstention would be considered a majority decision, but not unanimous.

Question Title

* 1. Safety decision:

Unanimous safe

Majority safe

Even split

Majority not safe

Unanimous not safe

Question Title

* 2. Effectiveness decision:

Unanimous effective

Majority effective

Even split

Majority not effective

Unanimous not effective

Question Title

* 3. Benefits Outweigh Risks decision:

Unanimous benefits outweigh risks

Majority benefits outweigh risks

Even split

Majority benefits do not outweigh risks

Unanimous benefits do not outweigh risks

Question Title

* 4. Please share your contact information so that we may send you the results when we've closed the survey.

Email (required):

First name (required):

Last name (required):

Question Title

* 5. Your position:

C-level

Managing Director

VP or SVP

Director

Manager

Physician / healthcare provider

Other

Question Title

* 6. Your role:

Medtech R&D

Medtech sales

Medtech business development

Medtech regulatory

Medtech other

Buy-side finance

Sell-side finance

Medicine / healthcare provider

Other

Question Title

* 7. Contact information

Company:

Phone:

Address:

City:

State:

Country: